Step by Stepa HemeOncBuddy patient portal

Lurbinectedin

Illustration: Lurbinectedin

Say it: lur-bih-NEK-teh-din · Brand names: Zepzelca

Lurbinectedin is a chemotherapy medicine that binds to DNA in cancer cells and stops them from making the proteins they need to grow.

What it is

Lurbinectedin attaches to DNA inside cancer cells. This blocks the cell from reading its genes and damages the DNA. The cancer cells then die.

Often used for

How you get it

Lurbinectedin is given through a vein (IV) over about 1 hour. It is usually given once every 3 weeks. You get anti-nausea medicine before each dose. Your schedule may be different.

Common side effects and what helps

Call your care team right away if you have

Before you start, tell your team

Good to know

Questions to ask

Side effect guides

Sources

Quick answers

What is Lurbinectedin?
Lurbinectedin is a chemotherapy medicine that binds to DNA in cancer cells and stops them from making the proteins they need to grow. Brand names: Zepzelca.
What is Lurbinectedin used for?
small cell lung cancer that has spread and came back after platinum chemotherapy; small cell lung cancer, as ongoing (maintenance) treatment with atezolizumab after first treatment.
How is Lurbinectedin given?
Lurbinectedin is given through a vein (IV) over about 1 hour. It is usually given once every 3 weeks. You get anti-nausea medicine before each dose. Your schedule may be different.
What are the common side effects of Lurbinectedin?
Feeling tired. Low blood counts, which raise your risk of infection and bleeding. Nausea and vomiting. Poor appetite. Muscle or joint aches. Constipation. Shortness of breath or cough.
When should I call my care team while taking Lurbinectedin?
A fever of 100.4 degrees Fahrenheit (38 degrees Celsius) or higher, or chills; Pain, swelling, or redness where the IV went in; Severe muscle pain or weakness, or dark brown urine; Yellow skin or eyes or dark urine; Bleeding or bruising that will not stop, black or bloody stools, or blood in your urine.

Last updated: 2026-10-27. Medically reviewed by Veli Bakalov, MD, medical oncologist (October 2026). General education from Step by Step, the patient portal of HemeOncBuddy.